亚裔美国人、夏威夷原住民和太平洋岛民 disaggregated 群体宫颈癌分期差异
该研究回顾性分析美国国家癌症数据库2004至2020年122,926例新诊断宫颈癌患者,其中5142例(4.2%)为亚裔美国人、夏威夷原住民或太平洋岛民。按来源国 disaggregated 后,太平洋岛民美国人转移性疾病就诊 odds 高于非西班牙裔白人(aOR 1.58),而华裔、越南裔、苗裔和印度/巴基斯坦裔美国人则较低。结论认为聚合评估掩盖了不同群体的差异。
要点
- 聚合的亚裔美国人、夏威夷原住民或太平洋岛民患者局部/区域期诊断比例为85.6%,高于非西班牙裔白人的58.7%。
- 太平洋岛民美国人转移性疾病就诊 odds 高于非西班牙裔白人(aOR 1.58,95%CI 1.21-2.06)。
- 以华裔美国人为参照,太平洋岛民、泰国裔、柬埔寨裔、夏威夷原住民和佬裔美国人转移性疾病就诊 odds 更高。
核心结论
- 对亚裔美国人、夏威夷原住民或太平洋岛民进行聚合评估会掩盖不同风险群体的结局差异。
- 太平洋岛民美国人和泰国裔美国人等边缘化群体可能面临不同的暴露和更大的结构性障碍,影响癌症筛查和早期诊断。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004至2020年122,926例新诊断宫颈癌患者数据。
- 亚裔美国人、夏威夷原住民或太平洋岛民患者按来源国进行 disaggregated 分析。
- 采用逻辑回归计算调整 odds 比(aOR),调整临床和社会人口学因素。
主要发现
- 122,926例宫颈癌患者中,5142例(4.2%)为亚裔美国人、夏威夷原住民或太平洋岛民。
- 非西班牙裔白人患者局部/区域期诊断比例为58.7%,亚裔美国人、夏威夷原住民或太平洋岛民患者为85.6%(χ2 P<.001)。
- 太平洋岛民美国人转移性疾病就诊 odds 高于非西班牙裔白人(aOR 1.58,95%CI 1.21-2.06,P=.001)。
- 华裔美国人(aOR 0.47,95%CI 0.37-0.59,P<.001)、越南裔美国人(aOR 0.54,95%CI 0.41-0.70,P<.001)、苗裔美国人(aOR 0.46,95%CI 0.22-0.97,P=.040)和印度/巴基斯坦裔美国人(aOR 0.76,95%CI 0.61-0.94,P=.013)转移性疾病就诊 odds 低于非西班牙裔白人。
- 以华裔美国人为参照,太平洋岛民美国人(aOR 3.44,95%CI 2.41-4.91,P<.001)、泰国裔美国人(aOR 2.79,95%CI 1.41-5.53,P=.003)、柬埔寨裔美国人(aOR 2.39,95%CI 1.29-4.42,P=.006)、夏威夷原住民美国人(aOR 2.23,95%CI 1.37-3.63,P=.001)和佬裔美国人(aOR 2.02,95%CI 1.13-3.61,P=.017)转移性疾病就诊 odds 更高。
临床怎么用
- 作者认为,未来需要关注基于社区的 disaggregated 研究和量身定制的干预措施,以缩小这些差距。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over 20 million people in the United States identified as Asian American, Native Hawaiian, or Pacific Islander in 2022. Despite the diversity of immigration histories, lived experiences, and health needs within the Asian American, Native Hawaiian, or Pacific Islander community, prior studies in cervical cancer have considered this group in aggregate. OBJECTIVE: We sought to analyze disparities in cervical cancer stage at presentation in the United States, focusing on disaggregated Asian American, Native Hawaiian, or Pacific Islander groups. STUDY DESIGN: Data from the United States National Cancer Database from 2004 to 2020 of 122,926 patients newly diagnosed with cervical cancer were retrospectively analyzed. Asian American, Native Hawaiian, or Pacific Islander patients were disaggregated by country of origin. Logistic regression, adjusted for clinical and sociodemographic factors, was used to calculate adjusted odds ratios. Higher adjusted odds ratios indicate an increased likelihood of metastatic versus nonmetastatic disease at diagnosis. RESULTS: Out of 122,926 patients with cervical cancer, 5142 (4.2%) identified as Asian American, Native Hawaiian, or Pacific Islander. Compared to non-Hispanic White patients, pooled Asian American, Native Hawaiian, or Pacific Islander patients presented at lower stages of cancer (non-Hispanic White: 58.7% diagnosed local/regional, Asian American, Native Hawaiian, or Pacific Islander : 85.6% at local/regional, χ2 P<.001). The largest Asian American, Native Hawaiian, or Pacific Islander subgroups included Filipino Americans (n=1051, 20.4% of Asian American, Native Hawaiian, or Pacific Islander), Chinese Americans (n=995, 19.4%), Asian Indian/Pakistani Americans (n=711, 13.8%), Vietnamese Americans (n=627, 12.2%), and Korean Americans (n=550, 10.7%) respectively. Asian American, Native Hawaiian, or Pacific Islander disaggregation revealed that Pacific Islander American patients had higher odds of presenting with metastatic disease (adjusted odds ratio 1.58, 95% confidence interval 1.21-2.06, P=.001) relative to non-Hispanic White patients. Conversely, Chinese American (adjusted odds ratio 0.47, 95% confidence interval 0.37-0.59, P<.001), Vietnamese American (adjusted odds ratio 0.54, 95% confidence interval 0.41-0.70, P<.001), Hmong American (adjusted odds ratio 0.46, 95% confidence interval 0.22-0.97, P=.040), and Indian/Pakistani American (adjusted odds ratio 0.76, 95% confidence interval 0.61-0.94, P=.013) patients were less likely to present with metastatic disease. Compared to the largest Asian American, Native Hawaiian, or Pacific Islander group (Chinese American), 9 other subgroups were more likely to present with metastatic disease. The largest differences were observed in Pacific Islander American (adjusted odds ratio 3.44, 95% confidence interval 2.41-4.91, P<.001), Thai American (adjusted odds ratio 2.79, 95% confidence interval 1.41-5.53, P=.003), Kampuchean American (adjusted odds ratio 2.39, 95% confidence interval 1.29-4.42, P=.006), Native Hawaiian American (adjusted odds ratio 2.23, 95% confidence interval 1.37-3.63, P=.001), and Laotian American (adjusted odds ratio 2.02, 95% confidence interval 1.13-3.61, P=.017). In contrast, Vietnamese American (adjusted odds ratio 1.20, 95% confidence interval 0.85-1.71, P=.303), and Hmong American (adjusted odds ratio 1.09, 95% confidence interval 0.50-2.37, P=.828) patients did not show a statistically significant difference in presenting with metastatic disease compared to Chinese American patients. CONCLUSION: Aggregated evaluation of the Asian American, Native Hawaiian, or Pacific Islander monolith masks disparities in outcomes for distinct populations at risk for equity gaps. This disaggregation study shows that marginalized groups within the larger Asian American, Native Hawaiian, or Pacific Islander population-including Pacific Islander American and Thai American patients-may face different exposures and larger structural barriers to cancer screening and early-stage diagnosis. A future focus on community-based disaggregated research and tailored interventions is necessary to close these gaps.
引用
- Ho FDV, Thaploo A, Wang K, et al. Cervical cancer disparities in stage at presentation for disaggregated Asian Americans, Native Hawaiians, and Pacific Islanders. Am J Obstet Gynecol. 2024. PMID: 39179090. doi:10.1016/j.ajog.2024.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。